Cerebral vascular disease and cognitive function in patients with lesions were positively correlated with the area, volume relationship, result (FPG), 2h postprandial plasma glucose (2hPG), HOMA-IR, glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and negatively correlated with high-density lipoprotein cholesterol (HDL-C); Type 2 diabetes mellitus patients had higher sVCAM-1 levels than those in the control group, and the level in the type 2 diabetes mellitus patients with coronary heart disease group was significantly higher than that of the pure sVCAM-1 type 2 diabetes mellitus group; Fluvastatin intervention resulted in varying degrees of decline in sVCAM-1 levels in patients with type 2 diabetes after treatment. Conclusion: sVCAM-1, as one of the most important adhesion molecules, participates in insulin resistance of type 2 diabetes complicated with coronary heart disease and its occurrence and development. Fluvastatin can significantly reduce the risk of type 2 diabetes patients with coronary artery disease complicated with sVCAM-1 level.
**Keywords**: Type 2 diabetes; Coronary heart disease; Vascular cell adhesion molecule 1; Fluvastatin
**CLC number**: R587.1; R541.4 Document code: A Article ID: 1000-2065 (2008): 12-0800-04
**Clinical research on the level of soluble vascular cell adhesion molecule-1 and the effect of fluvastatin intervention on it in type 2 diabetes mellitus complicated with coronary heart disease**
HUO Yan, CHEN Dezhi, WANG Zhaoling (Department of Endocrinology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221002, China)
**Abstract**: Objective To investigate the role of soluble vascular cell adhesion molecule-1 (sVCAM-1) in type 2 diabetes complicated with coronary heart disease (CHD) and elucidate the mechanism of the protective effects of fluvastatin intervention on these patients. Methods 40 normal subjects, 40 type 2 diabetics without CHD, and 40 type 2 diabetics with CHD underwent examinations of body mass index (BMI), blood lipids, blood sugar, HOMA-IR, and their sVCAM-1 was determined by ELISA before fluvastatin treatment. All diabetics received fluvastatin intervention for 24 weeks prior to a second sVCAM-1 detection by ELISA so as to establish contrast of therapeutic stages and research on the correlations between these indices. Simultaneously, their FPG, 2hPG, HOMA-IR, HbA1c, TG, TC, LDL-C, Moncler Italia, HDL-C.